Features | Partner Sites | Information | LinkXpress
Sign In
Demo Company

Biotech Researchers Invited to Use an Automated, High-Capacity Target Capture-Sequencing Service

By BiotechDaily International staff writers
Posted on 13 Jan 2012
Researchers in need of DNA sequencing data can avail themselves of a new service that provides completely automated, high capacity, target capture-sequencing data, and streamlines sample preparation for targeted next-generation sequencing.

The new service, called targeted resequencing, is an innovation of Beckman Coulter Genomics (Danvers, MA, USA), a leading provider of genomic services and nucleic acid purification products.

Functionally, the service relies on the combination of “Agilent SureSelect Target Enrichment” technology with Beckman Coulter’s “SPRIworks Fragment Library System” for automated library construction and “Biomek Laboratory Automation Workstation” for liquid handling. This platform provides high quality, reproducible samples ready for sequencing. Beckman Coulter Genomics automated target capture solution allows for whole exome capture or custom targeting of genomic regions of interest. Sequencing on the Illumina GAII or HiSeq 2000 instruments provides accurate data with reduced project turnaround time resulting from workflow automation and flexible sample multiplexing options.

“By automating this pipeline and maximizing our target capture sequencing capacity, we are able to offer our customers a high-throughput solution, with faster project turnaround times and reproducible sequencing data,” said Dr. William Donahue, manager of molecular biology for Beckman Coulter Genomics. “Our LIMS [laboratory information management system] sample tracking also enables large numbers of samples to be processed at the same time, significantly reducing the risk of sample mix-up that exists in a manual process.”

Results are delivered via a secure FTP site or are shipped on a portable hard drive depending upon the size of the dataset.

Related Links:

Beckman Coulter Genomics


Drug Discovery

view channel
Image: Use of catchphrase terms like “breakthrough” and “promising” in public news media presenting new drugs tends to result in incorrect assumptions and conclusions about the meaning and significance of criteria for FDA breakthrough-designated and accelerated-approval drugs (Photo courtesy of Dartmouth Institute).

Words That Inappropriately Enhance Perception of New Drug’s Effectiveness

Researchers have found that using the words “breakthrough” and “promising” in presenting a new drug to the general public often has a dramatic effect on judgment about its effectiveness.... Read more

Lab Technologies

view channel

New Genomic Research Kit Simplifies Exome Studies

An exciting new tool is now available for biotech researchers working in the field of genomic analysis. The human exome is critical to our genetic make-up and is generally accepted as having the greatest influence on how the genetic blueprint is utilized. The exome is defined as all coding exons in the genome and is... Read more


view channel

Collaboration Agreement to Boost Discovery of Fully Human Antibodies for Therapeutic Use

The discovery of fully human antibodies for therapeutic use will be boosted by a recently announced collaboration between a major university research center and a dynamic biopharmaceutical development company. Regeneron Pharmaceuticals, Inc. (Tarrytown, New York, USA) and The Experimental Therapeutics Institute (ETI)... Read more


17 Oct 2015 - 21 Oct 2015
25 Oct 2015 - 29 Oct 2015
16 Nov 2015 - 19 Nov 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.